Vwa5a, also known as Breast Cancer Suppressor Candidate-1 (BCSC-1), is likely involved in tumor-suppression related functions [3,4,5]. Its potential role in tumor suppression suggests it may be associated with pathways regulating cell growth, proliferation, and metastasis. The gene is of biological importance as its abnormal expression is linked to cancer development. Genetic models could be valuable in further exploring its functions.

In breast cancer, low Vwa5a expression is associated with shorter metastasis-free intervals and poor survival, especially in hormone-receptor-positive breast cancers. In-vitro experiments confirm its tumor-suppressive effect on breast cancer cells in hormone-receptor-positive and triple-negative breast cancer cell lines. Decreasing nuclear expression of Vwa5a is associated with advanced T stage and lymphatic invasion [1].

In colon cancer, Vwa5a is part of an apoptosis-related gene prognostic index (ARGPI). High-risk scores related to the ARGPI, including Vwa5a, are associated with a cell-cycle-pathway enrichment, high TP53 and KRAS mutation rates, and an immunosuppressive state, while low-risk scores are related to drug-metabolism-related pathways and an active immune function [2].

In conclusion, Vwa5a plays a significant role in tumor-suppression, with its abnormal expression linked to poor prognosis in breast and colon cancers. Studies on Vwa5a using various models contribute to understanding cancer-related biological processes, providing potential insights for cancer prognosis and treatment strategies.